We are live on ! Find out more
TNDM icon

Tandem Diabetes Care

279 hedge funds and large institutions have $3.6B invested in Tandem Diabetes Care in 2020 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 80 increasing their positions, 106 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more capital invested

Capital invested by funds: $3.24B → $3.6B (+$358M)

1.75% more ownership

Funds ownership: 92.03%93.78% (+1.7%)

0% more funds holding in top 10

Funds holding in top 10: 88 (0)

2% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 55

2% less call options, than puts

Call options by funds: $35.8M | Put options by funds: $36.6M

2% less funds holding

Funds holding: 284279 (-5)

25% less repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 106

Holders
279
Holders Change
-5
Holders Change %
-1.76%
% of All Funds
6.15%
Holding in Top 10
8
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.18%
New
54
Increased
80
Reduced
106
Closed
55
Calls
$35.8M
Puts
$36.6M
Net Calls
-$758K
Net Calls Change
-$7.24M
Name Holding Trade Value Shares
Change
Change in
Stake
LPL Financial
151
LPL Financial
California
$915K +$13.6K +194 +1%
AIA
152
Affinity Investment Advisors
California
$854K +$303K +4,320 +48%
VFA
153
Voya Financial Advisors
Connecticut
$818K -$19.5K -279 -2%
Envestnet Asset Management
154
Envestnet Asset Management
Illinois
$804K +$601K +8,572 +218%
ASRS
155
Arizona State Retirement System
Arizona
$803K +$875K +12,486 New
CSS
156
Cubist Systematic Strategies
Connecticut
$759K +$284K +4,050 +52%
NA
157
NewEdge Advisors
Louisiana
$739K -$461K -6,576 -36%
Commonwealth Equity Services
158
Commonwealth Equity Services
Massachusetts
$721K +$205K +2,920 +35%
ACM
159
AlphaCrest Capital Management
New York
$714K +$476K +6,800 +158%
Bank Julius Baer & Co
160
Bank Julius Baer & Co
Switzerland
$712K +$776K +11,076 New
FMT
161
First Mercantile Trust
Tennessee
$679K -$30.8K -440 -4%
TD Asset Management
162
TD Asset Management
Ontario, Canada
$676K -$112K -1,600 -13%
Parallax Volatility Advisers
163
Parallax Volatility Advisers
California
$670K +$490K +6,994 +204%
XK
164
Xact Kapitalforvaltning
Sweden
$669K
OC
165
Oppenheimer & Co
New York
$662K -$2.32M -33,093 -76%
P8IP
166
Pier 88 Investment Partners
California
$661K -$126K -1,800 -15%
AB
167
Amalgamated Bank
New York
$660K -$48.5K -692 -6%
WMSA
168
Weiss Multi-Strategy Advisers
New York
$656K -$897K -12,799 -56%
LSA
169
L & S Advisors
California
$631K +$105K +1,496 +18%
Wolverine Trading
170
Wolverine Trading
Illinois
$631K +$650K +9,274 New
AFP
171
Ausdal Financial Partners
Iowa
$626K +$6.31K +90 +1%
FG
172
Formula Growth
Quebec, Canada
$611K +$666K +9,500 New
1CM
173
1492 Capital Management
Wisconsin
$610K +$664K +9,478 New
Jane Street
174
Jane Street
New York
$597K -$1.67M -23,892 -72%
UCFA
175
United Capital Financial Advisors
Texas
$568K +$619K +8,831 New

TNDM Hedge Fund Activity: Q1 2020 in Review

279 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q1 2020, worth a combined $3.6B — up 11% from $3.24B a quarter earlier.

Sellers outnumbered buyers: 55 funds closed out of TNDM and 54 opened new positions — a net loss of 1 holder — while 106 trimmed existing stakes and 80 added.

The largest buyer was Wellington Management Group, adding an estimated $262M. The largest seller was OrbiMed, exiting entirely with an estimated $68M sold.

  • 279 institutional investors held Tandem Diabetes Care (TNDM) as of Q1 2020, down from 284 in Q4 2019.
  • Funds reported $3.6B of Tandem Diabetes Care stock for Q1 2020, up 11% quarter-over-quarter.
  • 54 funds opened new Tandem Diabetes Care positions in Q1 2020 and 55 closed out, a net change of -1 holder.
  • The largest Tandem Diabetes Care buyer in Q1 2020 was Wellington Management Group, an estimated $262M added.
  • The largest Tandem Diabetes Care seller in Q1 2020 was OrbiMed, an estimated $68M sold.

Based on aggregated 13F filings for Q1 2020.